Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Source: Eurosurveillance - July 16, 2020 Category: Infectious Diseases Authors: Heli Harvala, Jennifer Mehew, Matthew L Robb, Samreen Ijaz, Steven Dicks, Monika Patel, Nicholas Watkins, Peter Simmonds, Tim Brooks, Rachel Johnson, Robin Gopal, David J Roberts, Maria Zambon and the NHS Blood and Transplant Convalescent Plasma Testing G Source Type: research